The Flagship West Coast Biomarker Meeting Driving LBx Excellence
Whether your team is running dose escalation, looking to build MRD into a registrational trial, seeking a new assay partner, or using liquid biopsy for internal decision making, the 11th Liquid Biopsy for Precision Oncology Summit West Coast delivers tailored insights to your needs.
With two content tracks spanning the full clinical development arc and offering experiences from leading teams at every stage, you are guaranteed to walk away equipped with ideas you can put into action immediately.
Hear exclusive pharma and biotech perspectives, build connections with new and old faces, and brainstorm solutions so that you can enhance your ctDNA strategy before the next readout.
Are You Getting Full Value from Your Liquid Biopsy Investment?
Actionable Takeaways, Whatever Your Stage
First-in-Human: Make Every Dose Decision Count
See how Kura Oncology built longitudinal ctDNA into a phase I combination study, and how Takeda keeps serial plasma samples clean enough to trust at every timepoint.
Mid-Stage: Know It Is Working Before the Scan Does
Hear new ctDNA response data from AbbVie in ADC-treated tumors, discover Amgen's KRAS G12C colorectal experience and gain learnings from Zentalis Pharmaceuticals on ovarian cancer, before debating when to act on molecular progression.
Late-Stage: Build the Case for MRD as an Endpoint
AstraZeneca's regulatory team and Johnson & Johnson's diagnostics leaders unpack what the myeloma precedent transfers to solid tumors, and what bladder cancer MRD has taught them so far.
Beyond Mutations: Layer the Signal
Cell-free RNA, methylation, protein and spatial data go head-to-head with genomics, in a panel featuring perspectives from Pfizer, Regeneron, AstraZeneca and Johnson & Johnson.
From Great Test to Patient Access
BLOODPAC shares real-world adoption strategies, and Alexion Pharmaceuticals demonstrates how validation, laboratory and reimbursement pathways turn blood tests into standard practice.
Beyond Oncology: Reuse the Playbook
Ionis Pharmaceuticals gives their insights on blood-based biomarkers in neurodegeneration and Alexion Pharmaceuticals shares theirs on rare disease diagnostics to show where liquid biopsy lessons can travel next.
Discover the Complete LBx Event Program
- Identify Your Sessions Fast: See exactly where dose optimization, MRD endpoints and resistance monitoring are covered, so you can plan your team around the decisions you face.
- Assign Each Team Member to a Track: With two content tracks running in parallel, make sure your team benefits from all the unmissable insights available.
- Preview Live Program Data: Get a first look at what AstraZeneca, Amgen, AbbVie, Johnson & Johnson and Kura Oncology are learning from ctDNA in their real-world trials.
- Align Your Cross-Functional Teams: Pass on to colleagues who sign off on assays, partners and budgets so that your entire team are united on the cases for acting.
What's New for 2027?
Two Refocused Tracks
Delve deeper on your stage of adoption with two new tracks on Dose Optimization & Therapeutic Monitoring, and Patient Selection & Diagnostics.
A Regulatory Start to Day Two
Day Two will start with the evidence package needed to make MRD an accepted trial endpoint.
Personalized Cancer Vaccines
CellVax and Nykode Therapeutics join the speaker faculty for the first time to discuss using ctDNA to select targets, stratify patients and track response.
RNA & Multi-Omic Signals
Listen to UC San Diego talk on cell-free RNA, alongside a live debate on methylation, protein and fragmentomic signal.
Liquid Biopsy Beyond Oncology
To reflect the direction of the field, content on neurodegeneration and rare disease will close the program on Day Two.
Attending Companies Include
Discover the Event Program
See where leading teams at AstraZeneca, Amgen, Pfizer and Johnson & Johnson are taking ctDNA next, from dose finding through to MRD endpoints.
Prioritize Partnering With Us
Place your liquid biopsy platform in front of the pharma teams choosing assay partners for their next trials, before the vendor landscape settles.
Join 250+ Biopharma Peers
Meet the translational and precision medicine experts shaping future liquid biopsy strategies, so you can return to your team with actionable plans to implement in 2027 and beyond.